Safety and efficacy of sodium and meglumine ioxaglate (Hexabrix) and Hypaque M60% in contrast-enhanced computed cranial tomographic scanning. A double-blind clinical study.
The safety and efficacy of sodium and meglumine ioxaglate (Hexabrix, Mallinckrodt, Inc., St. Louis, MO), a new low-osmolality contrast agent, and Hypaque Meglumine 60% (Wintrop-Breon, Inc., New York, NY) were compared for contrast-enhanced computed cranial tomographic scanning. Fifty-two patients with possible enhancing lesions of the brain received a total of 59 injections of either Hexabrix or Hypaque M60 in a double-blind, randomized fashion. Hexabrix was superior to Hypaque M60 in both subjective and objective patient tolerance. A lower incidence of heat and pain in patients receiving Hexabrix was believed to be related to its lower osmolality. Lesion enhancement with both Hexabrix and Hypaque M60 was excellent. There was a statistically significant increase in the degree of enhancement immediately after injection with Hexabrix. Hexabrix had less effect on the cardiovascular system than Hypaque M60. No neurologic complications or adverse reactions requiring treatment occurred in either group. Hexabrix is a suitable agent for intravenous contrast-enhancement for cranial CT.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000000981:diagnostic imaging*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging; D002986:Clinical Trials as Topic; D003974:Diatrizoate Meglumine / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007485:Ioxaglic Acid / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012119:Respiration / Q000187:drug effects; D014057:Tomography, X-Ray Computed
D003974:Diatrizoate Meglumine; D007485:Ioxaglic Acid